Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
MALVERN, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, along with the Board of Directors and Executive Management Team, will ring the Nasdaq Closing Bell on Monday, December 19, 2022.
Related news for (OCGN)
- Today’s Top Performers: MoBot’s Market Review 09/23/25 03:00 PM
- Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
- 24/7 Market News Snapshot 15 September, 2025 – Ocugen, Inc. Common Stock (NASDAQ:OCGN)
- Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
- Ocugen To Present at BIO International Convention 2025